Evidence map›Paper›PMID 42146335›Full record

ArticlebioRxiv : the preprint server for biology2026

Therapeutic targeting of fibrin-microglia interactions ameliorates Alzheimer's disease-related hyperexcitability and brain network dysfunction.

Kelli Lauderdale, Zhaoqi Yan, Andrew S Mendiola, Yutong Zhang, Dakota Mallen, Pranav Nambiar, Erica Brady, Stephanie R Miller, Rosa Meza Acevedo, Belinda Cabriga and 17 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Kelli LauderdaleGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Zhaoqi YanGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Andrew S MendiolaGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Yutong ZhangGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Dakota MallenGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Pranav NambiarGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Erica BradyGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Stephanie R MillerGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Rosa Meza AcevedoGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Belinda CabrigaGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Fred JiangGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Nick KalissGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Kevin ShenGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Jia ShinGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Jessica HerbertGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Keran MaDepartment of Neurobiology and Anatomy, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, 77030.
Jae Kyu RyuGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Ayushi AgrawalGladstone Institute of Data Science and Biotechnology; San Francisco, CA 94158, USA.
Renaud SchuckGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Maria Del Pilar S AlzamoraGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Jorge Sanz-RosDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Inma CobosDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jeffrey StavenhagenTherini Bio, 2108 N ST, Ste 4963, Sacramento, CA 95816, USA.
Aaron B KantorTherini Bio, 2108 N ST, Ste 4963, Sacramento, CA 95816, USA.
Mark H EllismanDepartment of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Katerina AkassoglouGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
Jorge J PalopGladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.

Funding

Project 4: Cross-species Dissection of Cellular Response to APOE Genotype and AD Pathology Using Single-cell Multi-omicsP01AG073082 · NIA · J. DAVID GLADSTONE INSTITUTES · PI MUCKE, LENNART · 2021 to 2025
$23.4M
UC San Diego FIRST ProgramU54CA272220 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MARIA ELENA MARTINEZ, Joann Trejo · 2022 to 2026
$21.2M
Neurovascular Interactions: Mechanisms, imaging, therapeutic potentialR35NS097976 · NINDS · J. DAVID GLADSTONE INSTITUTES · PI AKASSOGLOU, KATERINA · 2016 to 2023
$11.1M
Multidimensional mapping of vulnerable cell types in humanized Alzheimer's disease mouse modelsR01AG082147 · NIA · STANFORD UNIVERSITY · PI Inma Cobos, Jorge J Palop · 2023 to 2026
$9.3M
Optogenetic dissection of cellular and circuit mechanisms of network dysfunction and amyloid deposition in mouse models of Alzheimer's disease in vivoRF1AG062234 · NIA · J. DAVID GLADSTONE INSTITUTES · PI PALOP, JORGE J · 2018 to 2021
$3.8M
Deciphering molecular pathways of inhibitory interneuron dysfunction in Alzheimer's diseaseR01AG062629 · NIA · J. DAVID GLADSTONE INSTITUTES · PI PALOP, JORGE J · 2019 to 2023
$3.6M
Neurovascular Interactions: Mechanisms, Imaging, TherapeuticsR35NS143067 · NINDS · J. DAVID GLADSTONE INSTITUTES · PI AKASSOGLOU, KATERINA · 2025 to 2025
$1.4M
Machine Learning Approaches for Behavioral Phenotyping of Humanized Knock-in Models of Alzheimer's DiseaseK01AG083732 · NIA · J. DAVID GLADSTONE INSTITUTES · PI MILLER, STEPHANIE REGINA · 2023 to 2025
$452k
Epigenomic regulation of oxidative stress-producing innate immunity in neuroinflammationK99NS126707 · NINDS · J. DAVID GLADSTONE INSTITUTES · PI MENDIOLA, ANDREW S · 2022 to 2023
$242k
NCI NIH HHS U54 CA272220NIA NIH HHS K01 AG083732NIA NIH HHS P01 AG073082NIA NIH HHS R01 AG062629NIA NIH HHS R01 AG082147NIA NIH HHS RF1 AG062234NINDS NIH HHS K99 NS126707NINDS NIH HHS R35 NS097976NINDS NIH HHS R35 NS143067
6 · The paper itself

Abstract

Brain network dysfunction-including hyperexcitability, altered oscillations, and sleep disruption-is prominent in Alzheimer's disease (AD), but the contribution of vascular-neuroimmune processes to these alterations remains unclear. Here, we blocked the pro-inflammatory interaction of the blood protein fibrin with microglia using genetic (Fgg

Identifiers

PMID42146335
PMCPMC13174307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.